Eli Lilly's stock has fallen 20% from its 52-week high, with some outlets citing disappointing initial sales data for a new drug as a factor. The company has also made significant investments, including $7 billion in cancer research, and has bet $27 billion on its own future. The stock's movement is being closely watched, with some outlets suggesting it could potentially rise, while others note it is near crucial support levels.